Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against MoonLake Immunotherapeutics due to allegations of violations of federal securities laws, particularly following disappointing clinical trial results that led to a significant drop in the company's stock price [2][3][4]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses exceeding $75,000 in MoonLake between March 10, 2024, and September 29, 2025, to discuss their legal options [1][2]. - A federal securities class action has been filed against MoonLake, with a deadline of December 15, 2025, for investors to seek the role of lead plaintiff [2][5]. Group 2: Allegations Against MoonLake - The complaint alleges that MoonLake and its executives made false or misleading statements regarding the efficacy of their product SLK compared to BIMZELX, including claims about molecular targets and clinical benefits [3]. - Specific allegations include that SLK shares the same molecular targets as BIMZELX and that its unique structure does not provide superior clinical benefits [3]. Group 3: Stock Price Impact - Following the announcement of the Phase 3 VELA program results on September 28, 2025, which indicated that SLK did not demonstrate competitive efficacy relative to BIMZELX, MoonLake's stock price fell by $55.75 per share, or 89.9%, closing at $6.24 on September 29, 2025 [4].

Core Viewpoint - A class action lawsuit has been filed against MoonLake Immunotherapeutics for allegedly misleading investors regarding the efficacy of its drug candidate, sonelokimab (SLK), which reportedly failed to meet clinical benchmarks [3][4]. Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotech firm based in Zug, Switzerland, focusing on next-generation immunotherapies [2]. Legal Proceedings - The lawsuit is on behalf of investors who purchased MoonLake shares from March 10, 2024, to September 29, 2025, with a deadline of December 15, 2025, for investors to seek lead plaintiff status [1][2]. Allegations - The complaint claims that MoonLake promoted SLK as a breakthrough treatment but failed to disclose that it targets the same molecules as BIMZELX, an FDA-approved monoclonal antibody, indicating it was not clinically superior [3]. Stock Impact - Following the disclosure of Phase 3 trial results on September 28, 2025, which showed that SLK did not meet efficacy benchmarks, MoonLake's stock price plummeted by $55.75 per share, nearly 90% in one trading session [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of MoonLake Immunotherapeutics regarding a class action lawsuit due to alleged misleading statements about the company's drug candidate SLK and its comparison to BIMZELX [1][2]. Summary by Sections Allegations - The complaint alleges that during the class period from March 10, 2024, to September 29, 2025, the defendants made materially false and misleading statements and failed to disclose critical information regarding SLK, including: - SLK and BIMZELX share the same molecular targets, specifically the inflammatory cytokines IL-17A and IL-17F [1]. - SLK's unique Nanobody structure does not provide a superior clinical benefit compared to the traditional monoclonal structure of BIMZELX [1]. - The supposed increased tissue penetration of SLK's Nanobody structure does not translate to clinical efficacy [1]. - Defendants lacked a reasonable basis for their positive statements regarding SLK's superiority over monoclonal antibodies [1]. Next Steps for Shareholders - Shareholders who purchased MLTX shares during the specified class period are encouraged to register for the class action by December 15, 2025, to potentially become lead plaintiffs [2]. - Registration allows shareholders to enroll in a portfolio monitoring software for status updates throughout the case lifecycle [2]. Firm's Commitment - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit, fraud, and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions that inflated stock prices [3].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of MoonLake Immunotherapeutics during the specified Class Period of the upcoming lead plaintiff deadline on December 15, 2025 [1]. Group 1: Class Action Details - Investors who bought MoonLake common stock between March 10, 2024, and September 29, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6]. - The lawsuit claims that defendants made false or misleading statements regarding the efficacy of their product compared to traditional monoclonal antibodies, leading to investor damages when the truth was revealed [5]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience or resources [4]. - The Rosen Law Firm has a history of successful settlements in securities class actions, including a notable settlement against a Chinese company and significant recoveries for investors in previous years [4].

Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and its senior executives for potential violations of federal securities laws, following disappointing results from its Phase 3 clinical trials for sonelokimab [1][2][3]. Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases, particularly through its investigational drug sonelokimab [3]. Clinical Trials and Data - The company conducted Phase 3 VELA trials for sonelokimab, claiming strong clinical data from its Phase 2 MIRA trial that suggested higher clinical responses and differentiation from competitors [4]. - Allegations state that the clinical data and Nanobody structure of sonelokimab did not provide a superior clinical benefit compared to competitors, raising concerns about the drug's regulatory approval and commercial viability [5]. Stock Performance - Following the announcement of disappointing results from the VELA Phase 3 trials on September 28, 2025, MoonLake's stock price plummeted nearly 90%, from $61.99 per share to $6.24 per share [6].

Core Viewpoint - MoonLake Immunotherapeutics is facing a class action lawsuit due to allegations of misleading investors about the efficacy of its drug candidate SLK, particularly in comparison to the FDA-approved drug BIMZELX [1][3]. Company Overview - MoonLake Immunotherapeutics is a Swiss clinical-stage biotechnology company focused on inflammatory diseases driven by interleukin-17 (IL-17), with a specific emphasis on dermatology and rheumatology [1]. Class Action Details - The class action was filed on behalf of all investors who purchased or acquired MoonLake's common stock during the class period from March 10, 2024, to September 29, 2025 [1]. - The lawsuit claims that the company failed to disclose critical information regarding the differences between its drug SLK and monoclonal antibodies, including the lack of superior clinical benefits and efficacy [3]. Allegations Against the Company - The complaint outlines several key allegations: 1. SLK and BIMZELX target the same inflammatory cytokines IL-17A and IL-17F [3]. 2. SLK's unique Nanobody structure does not provide a clinical advantage over BIMZELX's monoclonal structure [3]. 3. The supposed increased tissue penetration of SLK does not correlate with improved clinical efficacy [3]. 4. The company lacked a reasonable basis for its positive claims regarding SLK's superiority [3]. Stock Price Impact - Following the announcement of the week-16 results from the Phase 3 VELA program on September 28, 2025, which indicated that SLK did not demonstrate competitive efficacy against BIMZELX, MoonLake's stock price plummeted by $55.75 per share, or 89.9%, closing at $6.24 on September 29, 2025 [4]. Next Steps for Shareholders - Shareholders interested in participating in the class action must submit their papers to the court by December 15, 2025, to serve as lead plaintiff [5]. - Shareholders can choose to remain absent from the case while still being eligible for recovery [5]. Legal Representation - Robbins LLP is leading the class action and operates on a contingency fee basis, meaning shareholders incur no fees or expenses unless a recovery is achieved [6].

Core Viewpoint - A class action securities lawsuit has been filed against MoonLake Immunotherapeutics, alleging securities fraud that affected investors between March 10, 2024, and September 29, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements regarding MoonLake's drug candidate SLK, asserting that it shares molecular targets with BIMZELX and that SLK's unique Nanobody structure does not provide superior clinical benefits [2]. - Allegations include that SLK's supposed increased tissue penetration does not translate to clinical efficacy, and thus the defendants lacked a reasonable basis for their positive claims about SLK's superiority over monoclonal antibodies [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until December 15, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States, with over 70 employees dedicated to serving clients [4].

Core Viewpoint - MoonLake Immunotherapeutics faces a securities class action lawsuit following the announcement of disappointing Phase 3 trial results for its product candidate sonelokimab (SLK), leading to a significant drop in share price by approximately 90% [1][2][6]. Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on treating skin inflammatory diseases driven by cytokines IL-17A and IL-17F [3]. Trial Results and Market Reaction - The Phase 3 trials for SLK revealed that only one of the two trials achieved statistical significance, with results showing substantially lower efficacy compared to the competitor's FDA-approved product, BIMZELX [6]. - Following the announcement on September 28, 2025, MoonLake's share price plummeted by $55.75, or about 90%, on September 29, 2025 [2][6]. Allegations of Misleading Information - The lawsuit claims that MoonLake misled investors regarding SLK's trial design and efficacy, asserting that the company made false statements about the advantages of SLK's Nanobody structure over traditional monoclonal antibodies [5]. - Specific allegations include misleading claims about SLK's potential clinical benefits and the distinction between Nanobodies and monoclonal antibodies [5]. Legal Proceedings - The class action lawsuit is focused on the propriety of MoonLake's statements about SLK's trial design and data, with a class period defined from March 10, 2024, to September 29, 2025 [3]. - The lead plaintiff deadline for the lawsuit is set for December 15, 2025 [3].

Core Viewpoint - MoonLake Immunotherapeutics is facing a class action securities lawsuit due to alleged securities fraud impacting investors between March 10, 2024, and September 29, 2025 [1]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements regarding MoonLake's drug candidate SLK, asserting that it shares molecular targets with BIMZELX and that SLK's unique Nanobody structure does not provide superior clinical benefits [2]. - It is alleged that the supposed increased tissue penetration of SLK does not translate to clinical efficacy, indicating a lack of reasonable basis for the positive claims made about SLK's superiority over traditional monoclonal antibodies [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until December 15, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, emphasizing that there is no financial obligation to participate [3]. Group 3: Legal Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States, with over 70 employees dedicated to serving clients [4].

Core Viewpoint - The Gross Law Firm is notifying shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX) about a class action lawsuit due to alleged misleading statements regarding the company's drug candidate SLK and its comparison to BIMZELX [1][3]. Group 1: Allegations - The complaint alleges that during the class period from March 10, 2024, to September 29, 2025, the defendants made materially false and/or misleading statements [3]. - Key allegations include that SLK and BIMZELX share the same molecular targets, and SLK's unique Nanobody structure does not provide superior clinical benefits over BIMZELX [3]. - It is also claimed that SLK's supposed increased tissue penetration does not translate to clinical efficacy, indicating a lack of reasonable basis for positive statements regarding SLK's superiority [3]. Group 2: Class Action Details - The deadline for shareholders to register for the class action is December 15, 2025, and there is no cost or obligation to participate [4]. - Shareholders who register will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle [4]. - The Gross Law Firm emphasizes its commitment to protecting investors' rights and ensuring responsible business practices [5].